8. ハンチントン病 Huntington disease Clinical trials / Disease details


臨床試験数 : 229 薬物数 : 197 - (DrugBank : 60) / 標的遺伝子数 : 84 - 標的パスウェイ数 : 158

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03980938
(ClinicalTrials.gov)
July 8, 20197/6/2019Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington DiseaseA Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)Huntington DiseaseDrug: neflamapimod;Other: PlaceboEIP Pharma IncVoisin Consulting, Inc.Terminated30 Years70 YearsAll15Phase 2United Kingdom
2EUCTR2018-004840-51-GB
(EUCTR)
26/06/201922/03/2019Study of Neflamapimod in Early-Stage Huntington Disease (HD)A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) Early-Stage Huntington Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Neflamapimod
Product Code: VX-745
INN or Proposed INN: Neflamapimod
Other descriptive name: VX-745
EIP Pharma, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
16 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom